Silexion’s CFO Discusses 2024 Milestones and The Company’s Innovative Approach to KRAS-Driven Cancers
Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments, we spoke with the Chief Financial Officer Mirit Horenshtein Hadar about the company’s achievements and strategic direction.










